• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With After Osimertinib First-Line Treatment.

作者信息

Corassa Marcelo, Abreu Rodrigo Fonseca, de Lima Vladmir Claudio Cordeiro, Torrezan Giovana Tardim, Cavalher Felicia Peterson, Silva Tullio Novaes, Oliveira Thiago Bueno de, Freitas Helano Carioca, Carraro Dirce Maria, Costa Felipe D'Almeida

机构信息

Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil.

Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil.

出版信息

JCO Precis Oncol. 2022 Oct;6:e2200367. doi: 10.1200/PO.22.00367.

DOI:10.1200/PO.22.00367
PMID:36201715
Abstract
摘要

相似文献

1
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With After Osimertinib First-Line Treatment.在奥希替尼一线治疗后，横纹肌肉瘤样转化作为表皮生长因子受体（EGFR）突变型肺腺癌对奥希替尼和萨伏替尼耐药的一种机制。
JCO Precis Oncol. 2022 Oct;6:e2200367. doi: 10.1200/PO.22.00367.
2
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.赛沃替尼单药治疗对一名原发性表皮生长因子受体（EGFR）L858R突变且伴有MET扩增的奥希替尼耐药非小细胞肺癌患者产生了显著疗效：一例病例报告
Anticancer Drugs. 2022 Nov 1;33(10):1186-1190. doi: 10.1097/CAD.0000000000001370. Epub 2022 Aug 10.
3
Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.奥希替尼耐药的 EGFR 驱动型肺癌 PDX 模型中 MET 通路激活的功能异质性。
Cancer Res Commun. 2024 Feb 8;4(2):337-348. doi: 10.1158/2767-9764.CRC-23-0321.
4
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.塔顿：奥希替尼联合塞来替尼、索凡替尼或度伐鲁单抗治疗 EGFR 突变型肺癌的多臂 Ib 期试验。
Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.
5
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma.卡马替尼与奥希替尼联合治疗EGFR突变型肺腺癌
J Thorac Oncol. 2020 Jan;15(1):e13-e15. doi: 10.1016/j.jtho.2019.07.027.
6
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.奥希替尼联合 savolitinib 治疗 EGFR 突变阳性、MET 扩增的非小细胞肺癌患者：EGFR 酪氨酸激酶抑制剂进展后的多中心、开放标签、Ib 期研究的中期结果。
Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3.
7
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.非小细胞肺癌对奥希替尼加 savolitinib 有反应。
Cancer Discov. 2020 Apr;10(4):487. doi: 10.1158/2159-8290.CD-RW2020-025. Epub 2020 Feb 14.
8
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an -Activating Mutation.具有 - 激活突变的肺腺癌细胞中对第三代 EGFR-TKI 奥希替尼产生耐药的多种机制。
Cells. 2022 Jul 14;11(14):2201. doi: 10.3390/cells11142201.
9
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.肺腺癌中一种新型获得性外显子 20 EGFR M766Q 突变介导奥希替尼耐药，但对奈拉替尼和波齐替尼敏感。
J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.
10
Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.一名EGFR突变型肺腺癌患者在对奥希替尼产生获得性耐药后，肿瘤先转变为鳞状细胞癌，后又转变为肉瘤样癌：病例报告
Clin Lung Cancer. 2021 Jul;22(4):e536-e541. doi: 10.1016/j.cllc.2020.06.026. Epub 2020 Jul 5.